| Autor: |
Симова, Я., Николов, Д., Димитров, Н., Корновски, В., Томова, В., Павлов, П., Красналиев, Й., Веков, Т. |
| Předmět: |
|
| Zdroj: |
Medical Review - Cardiovascular Diseases; 2021, Vol. 52 Issue 1, p3-7, 5p |
| Abstrakt: |
Introduction. Since the end of 2019, the pandemic caused by SARS-CoV2 has affected hundreds of millions of people, and the number of indirectly affected is many times higher. In addition to directly affecting lung tissue, the coronavirus infection predisposes patients to thrombotic events responsible for the occurrence of cardiovascular complications. The aim of our study was to observe patients with COVID-19 and acute coronary syndrome (ACS) and to evaluate the efficacy of anti-ischemic therapy with beta-blockers, molsidomine and trimetazidine. Results: We included 20 patients with COVID-19 and acute coronary syndrome. The mean age in the group was 67.5 ± 8.3 years, 40% (8) were women, 95% (19) had hypertension, dyslipidemia -- 90% (18 people), diabetes mellitus -- 35% (7). Selective coronary angiography was performed in all patients. In 55% of the patients (n= 11) we found a coronary lesion responsible for myocardial ischemia ("infarct-related artery") and percutaneous coronary intervention (PCI) was performed, while in the remaining 9 cases (45%) angiography did not reveal any significant coronary stenosis. In all patients we included anti-ischemic therapy with molsidomine 2 mg three times daily and trimetazidine MR 35 mg twice daily, as well as a beta-blocker, in addition to antiplatelet, antilipemic and other necessary medications. During hospitalization angina symptoms were resolved in all patients except one who required additional PCI. During the one-month follow-up, all patients remained asymptomatic and without subsequent hospitalizations. Reduction of the angina symptoms in patients with COVID-19 and ACS was valid for all the patients -- those with PCI and those without significant coronary stenosis. Conclusion: A significant percentage of patients with COVID-19 and ACS do not have coronary lesions, which suggests the presence of involvement of the small vessels. In this group, the administration of antiischemic therapy with beta-blockers, molsidomine and trimetazidine, in combination with antiplatelet and antilipemic therapy, results in rapid resolution and lasting response to angina symptoms. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
